CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis

被引：0
|
作者：
Minghuan Jiang
Joyce H. S. You
机构：
[1] The Chinese University of Hong Kong,School of Pharmacy, Faculty of Medicine
来源：
Cardiovascular Drugs and Therapy | 2017年 / 31卷
关键词：
Clopidogrel; Prasugrel; Ticagrelor; genotype; Acute coronary syndrome; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：39 / 49
页数：10
相关论文
共 50 条
  • [1] CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis
    Jiang, Minghuan
    You, Joyce H. S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2017, 31 (01) : 39 - 49
  • [2] Cost-effectiveness of CYP2C19 LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome
    Fu, Yu
    Zhang, Xin-yi
    Qin, Si-bei
    Nie, Xiao-yan
    Shi, Lu-wen
    Shao, Hong
    Liu, Han
    PHARMACOGENOMICS, 2020, 21 (01) : 33 - 42
  • [3] UNIVERSAL CLOPIDOGREL VERSUS CYP2C19-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS
    Jiang, M.
    You, J.
    VALUE IN HEALTH, 2015, 18 (03) : A19 - A19
  • [4] Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore
    Ji Heon Kim
    Doreen Su-Yin Tan
    Mark Yan Yee Chan
    The Pharmacogenomics Journal, 2021, 21 : 243 - 250
  • [5] Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore
    Kim, Ji Heon
    Tan, Doreen Su-Yin
    Chan, Mark Yan Yee
    PHARMACOGENOMICS JOURNAL, 2021, 21 (02): : 243 - 250
  • [6] THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION
    Reese, E. S.
    Mullins, C. D.
    Beitelshees, A. L.
    Onukwugha, E.
    VALUE IN HEALTH, 2010, 13 (03) : A175 - A175
  • [7] COST-EFFECTIVENESS OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK
    Kremers, F. C. C.
    Venema, E.
    Roozenbeek, B.
    Burke, J.
    Dippel, D. W.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 44 - 44
  • [8] COST-EFFECTIVENESS OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY FOR ACUTE MINOR ISCHEMIC STROKE OR TIA
    Kremers, F.
    Venema, E.
    Cras, T.
    Burke, J.
    Roozenbeek, B.
    Dippel, D.
    INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (2_SUPPL) : 19 - 19
  • [9] Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
    Nita A. Limdi
    Larisa H. Cavallari
    Craig R. Lee
    William B. Hillegass
    Ann M. Holmes
    Todd C. Skaar
    Maria Pisu
    Chrisly Dillon
    Amber L. Beitelshees
    Philip E. Empey
    Julio D. Duarte
    Vakaramoko Diaby
    Yan Gong
    Julie A. Johnson
    John Graves
    Shawn Garbett
    Zilu Zhou
    Josh F. Peterson
    The Pharmacogenomics Journal, 2020, 20 : 724 - 735
  • [10] Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
    Limdi, Nita A.
    Cavallari, Larisa H.
    Lee, Craig R.
    Hillegass, William B.
    Holmes, Ann M.
    Skaar, Todd C.
    Pisu, Maria
    Dillon, Chrisly
    Beitelshees, Amber L.
    Empey, Philip E.
    Duarte, Julio D.
    Diaby, Vakaramoko
    Gong, Yan
    Johnson, Julie A.
    Graves, John
    Garbett, Shawn
    Zhou, Zilu
    Peterson, Josh F.
    PHARMACOGENOMICS JOURNAL, 2020, 20 (05): : 724 - 735
12345